Technical Perspectives on Biotech Stocks -- PTC Therapeutics, Regeneron Pharma, Ritter Pharma, and Sangamo Therapeutics

NEW YORK, March 5, 2018 /PRNewswire/ -- strives to bring the best free research to the investment community. Today we are offering reports on PTCT, REGN, RTTR, and SGMO which can be accessed for free by signing up to Today, scans PTC Therapeutics, Inc. (NASDAQ: PTCT), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR), and Sangamo Therapeutics, Inc. (NASDAQ: SGMO). These companies belong to the Biotechnology sector, which harnesses biological processes to create technologies and products for a wide variety of challenges - from expanding crop sizes to treating disease. All you have to do is sign up today for this free limited time offer by clicking the link below.

PTC Therapeutics

South Plainfield, New Jersey headquartered PTC Therapeutics Inc.'s stock finished last Friday's session 3.83% higher at $25.73. A total volume of 579,505 shares was traded. The Company's shares have surged 61.62% over the previous three months and 95.22% over the past year. The stock is trading above its 50-day and 200-day moving averages by 16.75% and 37.05%, respectively. Additionally, shares of PTC Therapeutics, which focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes, have a Relative Strength Index (RSI) of 60.13.

On February 21st, 2018, PTC Therapeutics announced that the Company will host a webcast conference call on Tuesday, March 06th, 2018, at 4:30 p.m. ET to report its fourth-quarter and year-end 2017 financial results and provide an update on its business and outlook. A live, listen-only webcast of the conference call can be accessed under the investor relations section of the Company's website. Get the full research report on PTCT for free by clicking below at:

Regeneron Pharmaceuticals

On Friday, shares in Tarrytown, New York headquartered Regeneron Pharmaceuticals Inc. ended the session 2.70% higher at $330.47. The stock recorded a trading volume of 908,766 shares, which was higher than its three months average volume of 903,970 shares. The Company's shares are trading 7.94% below their 50-day moving average. Moreover, shares of Regeneron Pharma, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide, have an RSI of 44.85.

On February 12th, 2018, Regeneron Pharma announced the appointment of Marion McCourt as the Senior Vice President and Head of Commercial. Ms. McCourt joined that day to lead all aspects of product commercialization for the Company's currently-approved medicines and development-stage pipeline. She has more than two decades of broad experience in biopharmaceutical management, with an emphasis on commercial strategy and execution.

On February 21st, 2018, research firm Canaccord Genuity downgraded the Company's stock rating from 'Buy' to 'Hold' while revising its previous target price from $522 a share to $356 a share. Access the free research report on REGN now by signing up at:

Ritter Pharmaceuticals

Los Angeles, California headquartered Ritter Pharmaceuticals Inc.'s shares saw a correction of 13.20%, closing the session at $0.22. A total volume of 2.90 million shares was traded, which was above their three months average volume of 415,320 shares. The stock is trading 31.65% below its 50-day moving average. Additionally, shares of Ritter Pharma, which develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, have an RSI of 21.78.

On February 20th, 2018, Ritter Pharmaceuticals announced the appointment of William Chey, M.D. to its Medical Advisory Board. Dr. Chey is Nostrant Collegiate Professor of Gastroenterology & Nutrition Sciences, Director of the GI Physiology Laboratory, and Co-Director of the Michigan Bowel Control Program at Michigan Medicine. Are you already registered with Wall St. Equities? Do so now for free, and get the report on RTTR at:

Sangamo Therapeutics

Last Friday at the close, shares in Richmond, California headquartered Sangamo Therapeutics Inc. recorded a trading volume of 2.35 million shares, which was above their three months average volume of 1.89 million shares. The stock ended the session 3.19% higher at $24.25. The Company's shares have advanced 16.31% in the past month, 67.82% over the previous three months, and 427.17% over the past year. The stock is trading above its 50-day and 200-day moving averages by 23.58% and 77.97%, respectively. Furthermore, shares of Sangamo Therapeutics have an RSI of 60.69.

On February 12th, 2018, Sangamo Therapeutics announced the appointment of Heather D. Turner as Senior Vice President and General Counsel, effective immediately. Ms. Turner will oversee all legal matters for the Company and will report to its CEO. Aspiring Member, please take a moment to register below for your free research report on SGMO at:

Back to news